Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors
We examined the association between post-diagnosis statin use (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] inhibitors) and risk of breast cancer recurrence.
Materials and methods
The study included 1945 early stage breast cancer survivors participating in the Life After Cancer Epidemiology (LACE) Study. Women who were diagnosed from 1997 to 2000 and identified from the Kaiser Permanente Northern California (KPNC) Cancer Registry entered the cohort on average 2 years post-diagnosis. Information on statin use was obtained from the KPNC pharmacy database. A total of 210 breast cancer recurrences were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI).
The mean duration of statin use in the cohort among those who initiated use post-diagnosis was 1.96 years, and lipophilic statins were mainly used (97.8%). Starting statins after diagnosis was suggestive of a decreased risk of breast cancer recurrence (RR = 0.67; 95% CI: 0.39–1.13). Risk of recurrence decreased with increasing duration of statin use after diagnosis (p linear trend = 0.02).
Our findings provide initial support for an inverse association between post-diagnosis, lipophilic statin use and risk of breast cancer recurrence.
KeywordsStatins HMG-CoA inhibitors Breast cancer Recurrence Prognosis
This study was funded by the National Cancer Institute (R01 CA80027) and by the Utah Cancer Registry (N01 PC67000), with additional support from the State of Utah Department of Health. We thank Natalia Udaltsova and Erin Weltzien for statistical programming support. We thank all LACE Study staff and participants. Financial Support: National Cancer Institute (R01 CA80027 and N01-PC-67000).
- 12.Allison PD (1995) Survival analysis using SAS: a practical guide. SAS Press, Cary, NCGoogle Scholar
- 13.Hosmer DW, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New YorkGoogle Scholar
- 17.Esserman L, Campbell M, Shoemaker M, Lobo M, Marx C, Benz C (2004) Breast cancer inhibition by statins. J Clin Oncol 22(97s):(Suppl; abstr 1003)Google Scholar
- 20.Kumar AS, Campbell M, Benz CC, Esserman LJ (2006) A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 24(13):2127; author reply 2127–2128Google Scholar
- 24.Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C (2005) Statins to reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol 23(7s):(Suppl; abstr 514)Google Scholar
- 25.Mortimer J, Axelrod R, Zimbro K (2004) Effect of statins on breast cancer incidence: findings from the Sentara Health Plan. Proc Am Soc Clin Oncol 22(93):(abstr 373)Google Scholar
- 26.Selby JV, Smith DH, Johnson ES, Raebel MA, Friedman GD, McFarland BH (2005) Kaiser permanente medical care program. In: BL S (ed) Pharmacoepidemiology. Wiley, West Sussex, pp 241–259Google Scholar
- 27.Setoguchi S, Avorn J, Schneeweiss S (2005) Statins and the risk of colorectal cancer. N Engl J Med 353(9):952–954; author reply 952–954Google Scholar
- 28.The Internet Drug Index http://www.rxlist.com [Last accessed: December 12, 2006]